NASDAQ: ONCY · Life Sciences · 10 alerts · CIK 1129928
Share price
$0.3399Close, Nov 16
Market cap
$46.3M
Shares outstanding
136.14MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Oncolytics Biotech Inc filings on SEC EDGAR ↗
Oncolytics Biotech announced it will present a trial-in-progress abstract and e-poster for its REO 033 study at the ESMO Congress 2026. The study is a randomized Phase 2 trial evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Oncolytics Biotech provided an operational update on its GOBLET Phase 1/2 study, announcing the completion of enrollment and the expected receipt of a final grant payment from the Pancreatic Cancer Action Network (PanCAN). The company expects to report final results from Cohort 4 in Q4 2026 and initial results from Cohort 5 in the first half of 2027.
Oncolytics Biotech provided an update on its intellectual property strategy, including the issuance of new method of use patents for pelareorep in several countries and plans for a 'next generation' composition of matter patent. The company aims to extend its patent protection into the late 2040s, building on existing manufacturing protection that currently runs through 2044.
Oncolytics Biotech provided an operational update on its REO 033 randomized study for colorectal cancer, noting that substantially all clinical sites are now activated and enrollment is accelerating. The company expects to report interim clinical data from Part A of the study by year-end 2026 and has aligned with the FDA on a potential registration path for accelerated approval.